Genprex receives Nasdaq exception to continue listing; must meet $1 bid price by July 29, 2026

Genprex, Inc.

Nasdaq panel granted exception to continue listing; must demonstrate $1.00 minimum bid price compliance by July 29, 2026 and maintain through Dec 7, 2026.
Company implemented 1-for-22 reverse stock split on July 16, 2026 to help regain compliance with bid price requirement.
Panel retains jurisdiction until Dec 7, 2026; failure to maintain compliance could lead to delisting.
New Nasdaq rule effective July 22, 2026 allows immediate suspension if market value of listed securities falls below $5M for 30 consecutive days.
No assurance of maintaining compliance; delisting could harm capital raising, stock price, and business development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.